Skip to content
Movie Casting Call
Author:
Boehringer Ingelheim Limited
Boehringer Ingelheim’s New Quarterable Snap-Tab PREVICOX® (firocoxib) Chewable Tablets Provide Flexible Dosing for Dogs in the U.S.
October 7, 2026
Boehringer Ingelheim Celebrates Grand Opening of New U.S. Animal Health Headquarters in Johns Creek, Georgia
August 31, 2026
Boehringer Ingelheim Spotlights Next Generation of Veterinary Researchers
August 10, 2026
Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting improved metabolic health in people living with obesity
June 7, 2026
The hidden impact of veterinary care: new insights from a global survey of veterinarians
May 25, 2026
JASCAYD® (nerandomilast) approved in Japan, advancing global access to a new IPF and PPF treatment
May 18, 2026
Boehringer Ingelheim licenses preclinical antibody program from Immunitas Therapeutics to advance treatments for chronic inflammatory diseases
May 12, 2026
Boehringer Ingelheim and Eko Health Inc. launch new AI-based solution that detects heart murmurs in dogs
April 29, 2026
Boehringer Ingelheim’s novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase III trial
April 28, 2026
The Atlanta Braves and Boehringer Ingelheim Unveil 2026 “Dogout”
April 23, 2026
1
2
Next Page
→